Trump's Drug Price Achievements Questioned Following Separate Most Favored Nation Contract Disclosures with Lilly, Pfizer

Through a Freedom of Information Act request, Public Citizen on Saturday highlighted separate drug pricing agreements between the U.S. government and major pharmaceutical manufacturers, warning that these pacts could inflate medication costs globally. The nonprofit consumer advocacy organization revealed separate ‘Most Favored Nation’ contracts signed under President Donald Trump, cautioning that ambiguous provisions may encourage pharmaceutical companies to charge foreign consumers higher prices or discontinue overseas sales to maintain elevated pricing in America. Read Also: Trump's Drug Pricing Deals Could Lead To $529 Billion Savings For The Economy Over The Decade: Report Unredacted FOIA Records Reveal Secret Deals A Freedom of Information Act request over the weekend surfaced confidential pacts involving Pfizer Inc. (NYSE:PFE) and Eli Lilly and Co. (NYSE:LLY). Public Citizen indicated that heavy redactions continue to hinder public evaluation regarding the true financial consequences of these administration agreements. The oversight body specifically flagged unanswered questions regarding GLP-1 weight-loss medications manufactured by Lilly and Novo Nordisk A/S (NYSE:NVO). Public Citizen also questioned the truthfulness and timing of prior public statements concerning Pfizer. In 2025, Pfizer became the first Big Pharma firm to finalize a Most Favored Nation deal with the executive branch. In September, an additional nine pharmaceutical companies signed drug pricing agreements with the U.S. government. Missing Medicaid Negotiation Criteria Under GENEROUS While Public Citizen supports efforts aimed at reducing domestic medicine costs, the organization noted that corporate commentary regarding bottom-line impacts indicates Trump overstated his drug policy achievements. Neither Pfizer nor Lilly provided specific details explaining how the Centers for Medicare and Medicaid Services will establish coverage standards under the GENEROUS initiative for Medicaid. These missing terms remain vital for state officials deciding program participation and evaluating patient qualification. Under GENEROUS, state agencies must adopt federally mandated criteria, including step therapy or prior authorization requirements. CMS could potentially negotiate coverage rules forcing states to treat substantially larger patient populations without securing a corresponding price drop. Furthermore, Pfizer promised additional specifics in a separate GENEROUS agreement due by March 31, 2026. However, federal officials have failed to provide that document as of September 17, 2026. LLY/PFE Price Action: Eli Lilly shares were down 1.32% at $1149.47, and Pfizer shares were down 0.05% at $27.72 during premarket trading on Tuesday, according to Benzinga Pro data. Read Also: Elizabeth Warren Slams Trump as $6.9 Billion in Russia-Linked Payments Reportedly Slipped Through Global Banks Despite Sanctions Image via Shutterstock